Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: KBV Research | PRODUCT CODE: 1529317

Cover Image

PUBLISHER: KBV Research | PRODUCT CODE: 1529317

LAMEA T-cell Lymphoma Market Size, Share & Trends Analysis Report By Type, By Therapy (Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others), By Country and Growth Forecast, 2024 - 2031

PUBLISHED:
PAGES: 93 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 1500
PDF (Multi User License)
USD 1800
PDF (Corporate User License)
USD 2520

Add to Cart

The Latin America, Middle East and Africa T-cell Lymphoma Market would witness market growth of 11.3% CAGR during the forecast period (2024-2031).

The Brazil market dominated the LAMEA T-cell Lymphoma Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $75.9 million by 2031. The Argentina market is showcasing a CAGR of 12.2% during (2024 - 2031). Additionally, The UAE market would register a CAGR of 10.9% during (2024 - 2031).

Oncologists and hematologists specializing in lymphoma play a pivotal role in adoption. Their familiarity with emerging therapies, comfort with new treatment paradigms, and access to continuing medical education influence adoption rates. The heterogeneity of these lymphomas necessitates personalized treatment approaches. Adoption rates are influenced by patient-specific factors such as disease subtype, stage, molecular profile, comorbidities, and treatment goals aligned with patient preferences.

The availability and accessibility of advanced diagnostic technologies, including molecular profiling, PET-CT imaging, and biomarker testing, impact treatment decisions and the adoption of targeted therapies tailored to individual patient needs. The availability of comprehensive cancer centers, specialized clinics, and multidisciplinary care teams capable of delivering complex therapies and supportive care influences adoption rates. Healthcare infrastructure development in underserved regions is crucial for equitable access to innovative treatments.

The UAE's healthcare expansion positions it as a leading destination for medical tourism, with specialized oncology centers and hospitals attracting international patients seeking advanced treatments for these lymphomas. This influx of international patients contributes to the local healthcare economy and fosters collaborations with global healthcare providers. According to the International Trade Administration (ITA), in the UAE's 2022 federal budget, a total of USD 15.8 billion (AED 58.931 billion) was approved for public spending, of which 8.4% is dedicated to healthcare. Additionally, UAE's Vision 2040 has healthcare as a priority sector for the UAE government, and the country will continue to be an attractive location for establishing a regional distribution center for healthcare services. Investments in healthcare infrastructure in the UAE result in state-of-the-art oncology facilities equipped with the latest diagnostic technologies and treatment modalities for these lymphomas. This includes proton therapy, robotic surgery, and personalized medicine approaches that enhance treatment precision and patient outcomes. Therefore, increasing ageing population and rising healthcare sector budget in the region is driving the growth of the market.

Based on Type, the market is segmented into Peripheral (Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-immuno-blastic T-cell Lymphoma, and Others) and Lymphoblastic. Based on Therapy, the market is segmented into Chemotherapy, Radiotherapy, Immunotherapy, Stem Cell Transplantation, and Others.Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.

List of Key Companies Profiled

  • Bristol Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • Eisai Co., Ltd
  • Acrotech Biopharma Inc. (Aurobindo Pharma USA)
  • Shenzhen Chipscreen Biosciences Co., Ltd.
  • Citius Pharmaceuticals, Inc.
  • Genor Biopharma Co. Ltd.
  • Innate Pharma SA
  • Dizal Pharmaceutical Co. Ltd.

LAMEA T-cell Lymphoma Market Report Segmentation

By Type

  • Peripheral
    • Cutaneous T-cell Lymphoma
    • Anaplastic Large Cell Lymphoma
    • Angio-immuno-blastic T-cell Lymphoma
    • Others
  • Lymphoblastic

By Therapy

  • Chemotherapy
  • Radiotherapy
  • Immunotherapy
  • Stem Cell Transplantation
  • Others

By Country

  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Table of Contents

Chapter 1. Market Scope & Methodology

  • 1.1 Market Definition
  • 1.2 Objectives
  • 1.3 Market Scope
  • 1.4 Segmentation
    • 1.4.1 LAMEA T-cell Lymphoma Market, by Type
    • 1.4.2 LAMEA T-cell Lymphoma Market, by Therapy
    • 1.4.3 LAMEA T-cell Lymphoma Market, by Country
  • 1.5 Methodology for the research

Chapter 2. Market at a Glance

  • 2.1 Key Highlights

Chapter 3. Market Overview

  • 3.1 Introduction
    • 3.1.1 Overview
      • 3.1.1.1 Market Composition and Scenario
  • 3.2 Key Factors Impacting the Market
    • 3.2.1 Market Drivers
    • 3.2.2 Market Restraints
    • 3.2.3 Market Opportunities
    • 3.2.4 Market Challenges
  • 3.3 Porter Five Forces Analysis

Chapter 4. LAMEA T-cell Lymphoma Market by Type

  • 4.1 LAMEA Peripheral Market by Country
  • 4.2 LAMEA T-cell Lymphoma Market by Peripheral Type
    • 4.2.1 LAMEA Cutaneous T-cell Lymphoma Market by Country
    • 4.2.2 LAMEA Anaplastic Large Cell Lymphoma Market by Country
    • 4.2.3 LAMEA Angio-immuno-blastic T-cell Lymphoma Market by Country
    • 4.2.4 LAMEA Others Market by Country
  • 4.3 LAMEA Lymphoblastic Market by Country

Chapter 5. LAMEA T-cell Lymphoma Market by Therapy

  • 5.1 LAMEA Chemotherapy Market by Country
  • 5.2 LAMEA Radiotherapy Market by Country
  • 5.3 LAMEA Immunotherapy Market by Country
  • 5.4 LAMEA Stem Cell Transplantation Market by Country
  • 5.5 LAMEA Others Market by Country

Chapter 6. LAMEA T-cell Lymphoma Market by Country

  • 6.1 Brazil T-cell Lymphoma Market
    • 6.1.1 Brazil T-cell Lymphoma Market by Type
      • 6.1.1.1 Brazil T-cell Lymphoma Market by Peripheral Type
    • 6.1.2 Brazil T-cell Lymphoma Market by Therapy
  • 6.2 Argentina T-cell Lymphoma Market
    • 6.2.1 Argentina T-cell Lymphoma Market by Type
      • 6.2.1.1 Argentina T-cell Lymphoma Market by Peripheral Type
    • 6.2.2 Argentina T-cell Lymphoma Market by Therapy
  • 6.3 UAE T-cell Lymphoma Market
    • 6.3.1 UAE T-cell Lymphoma Market by Type
      • 6.3.1.1 UAE T-cell Lymphoma Market by Peripheral Type
    • 6.3.2 UAE T-cell Lymphoma Market by Therapy
  • 6.4 Saudi Arabia T-cell Lymphoma Market
    • 6.4.1 Saudi Arabia T-cell Lymphoma Market by Type
      • 6.4.1.1 Saudi Arabia T-cell Lymphoma Market by Peripheral Type
    • 6.4.2 Saudi Arabia T-cell Lymphoma Market by Therapy
  • 6.5 South Africa T-cell Lymphoma Market
    • 6.5.1 South Africa T-cell Lymphoma Market by Type
      • 6.5.1.1 South Africa T-cell Lymphoma Market by Peripheral Type
    • 6.5.2 South Africa T-cell Lymphoma Market by Therapy
  • 6.6 Nigeria T-cell Lymphoma Market
    • 6.6.1 Nigeria T-cell Lymphoma Market by Type
      • 6.6.1.1 Nigeria T-cell Lymphoma Market by Peripheral Type
    • 6.6.2 Nigeria T-cell Lymphoma Market by Therapy
  • 6.7 Rest of LAMEA T-cell Lymphoma Market
    • 6.7.1 Rest of LAMEA T-cell Lymphoma Market by Type
      • 6.7.1.1 Rest of LAMEA T-cell Lymphoma Market by Peripheral Type
    • 6.7.2 Rest of LAMEA T-cell Lymphoma Market by Therapy

Chapter 7. Company Profiles

  • 7.1 Bristol Myers Squibb Company
    • 7.1.1 Company Overview
    • 7.1.2 SWOT Analysis
  • 7.2 Daiichi Sankyo Company, Limited
    • 7.2.1 Company Overview
    • 7.2.2 SWOT Analysis
  • 7.3 Eisai Co., Ltd.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Analysis
    • 7.3.3 Segmental and Regional Analysis
    • 7.3.4 Research & Development Expenses
    • 7.3.5 SWOT Analysis
  • 7.4 Acrotech Biopharma Inc. (Aurobindo Pharma USA)
    • 7.4.1 Company Overview
  • 7.5 Shenzhen Chipscreen Biosciences Co., Ltd.
    • 7.5.1 Company Overview
  • 7.6 Citius Pharmaceuticals, Inc.
    • 7.6.1 Company Overview
    • 7.6.2 Recent strategies and developments:
      • 7.6.2.1 Trials and Approvals:
  • 7.7 Genor Biopharma Co. Ltd
    • 7.7.1 Company Overview
    • 7.7.2 Financial Analysis
    • 7.7.3 Research & Development Expenses
  • 7.8 Innate Pharma SA
    • 7.8.1 Company Overview
    • 7.8.2 Financial Analysis
    • 7.8.3 Research & Development Expenses
  • 7.9 Dizal Pharmaceutical Co. Ltd.
    • 7.9.1 Company Overview
    • 7.9.2 Recent strategies and developments:
      • 7.9.2.1 Trials and Approvals:

LIST OF TABLES

  • TABLE 1 LAMEA T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 2 LAMEA T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 3 LAMEA T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 4 LAMEA T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 5 LAMEA Peripheral Market by Country, 2020 - 2023, USD Million
  • TABLE 6 LAMEA Peripheral Market by Country, 2024 - 2031, USD Million
  • TABLE 7 LAMEA T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 8 LAMEA T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 9 LAMEA Cutaneous T-cell Lymphoma Market by Country, 2020 - 2023, USD Million
  • TABLE 10 LAMEA Cutaneous T-cell Lymphoma Market by Country, 2024 - 2031, USD Million
  • TABLE 11 LAMEA Anaplastic Large Cell Lymphoma Market by Country, 2020 - 2023, USD Million
  • TABLE 12 LAMEA Anaplastic Large Cell Lymphoma Market by Country, 2024 - 2031, USD Million
  • TABLE 13 LAMEA Angio-immuno-blastic T-cell Lymphoma Market by Country, 2020 - 2023, USD Million
  • TABLE 14 LAMEA Angio-immuno-blastic T-cell Lymphoma Market by Country, 2024 - 2031, USD Million
  • TABLE 15 LAMEA Others Market by Country, 2020 - 2023, USD Million
  • TABLE 16 LAMEA Others Market by Country, 2024 - 2031, USD Million
  • TABLE 17 LAMEA Lymphoblastic Market by Country, 2020 - 2023, USD Million
  • TABLE 18 LAMEA Lymphoblastic Market by Country, 2024 - 2031, USD Million
  • TABLE 19 LAMEA T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 20 LAMEA T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 21 LAMEA Chemotherapy Market by Country, 2020 - 2023, USD Million
  • TABLE 22 LAMEA Chemotherapy Market by Country, 2024 - 2031, USD Million
  • TABLE 23 LAMEA Radiotherapy Market by Country, 2020 - 2023, USD Million
  • TABLE 24 LAMEA Radiotherapy Market by Country, 2024 - 2031, USD Million
  • TABLE 25 LAMEA Immunotherapy Market by Country, 2020 - 2023, USD Million
  • TABLE 26 LAMEA Immunotherapy Market by Country, 2024 - 2031, USD Million
  • TABLE 27 LAMEA Stem Cell Transplantation Market by Country, 2020 - 2023, USD Million
  • TABLE 28 LAMEA Stem Cell Transplantation Market by Country, 2024 - 2031, USD Million
  • TABLE 29 LAMEA Others Market by Country, 2020 - 2023, USD Million
  • TABLE 30 LAMEA Others Market by Country, 2024 - 2031, USD Million
  • TABLE 31 LAMEA T-cell Lymphoma Market by Country, 2020 - 2023, USD Million
  • TABLE 32 LAMEA T-cell Lymphoma Market by Country, 2024 - 2031, USD Million
  • TABLE 33 Brazil T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 34 Brazil T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 35 Brazil T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 36 Brazil T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 37 Brazil T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 38 Brazil T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 39 Brazil T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 40 Brazil T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 41 Argentina T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 42 Argentina T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 43 Argentina T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 44 Argentina T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 45 Argentina T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 46 Argentina T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 47 Argentina T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 48 Argentina T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 49 UAE T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 50 UAE T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 51 UAE T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 52 UAE T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 53 UAE T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 54 UAE T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 55 UAE T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 56 UAE T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 57 Saudi Arabia T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 58 Saudi Arabia T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 59 Saudi Arabia T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 60 Saudi Arabia T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 61 Saudi Arabia T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 62 Saudi Arabia T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 63 Saudi Arabia T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 64 Saudi Arabia T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 65 South Africa T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 66 South Africa T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 67 South Africa T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 68 South Africa T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 69 South Africa T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 70 South Africa T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 71 South Africa T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 72 South Africa T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 73 Nigeria T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 74 Nigeria T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 75 Nigeria T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 76 Nigeria T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 77 Nigeria T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 78 Nigeria T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 79 Nigeria T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 80 Nigeria T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 81 Rest of LAMEA T-cell Lymphoma Market, 2020 - 2023, USD Million
  • TABLE 82 Rest of LAMEA T-cell Lymphoma Market, 2024 - 2031, USD Million
  • TABLE 83 Rest of LAMEA T-cell Lymphoma Market by Type, 2020 - 2023, USD Million
  • TABLE 84 Rest of LAMEA T-cell Lymphoma Market by Type, 2024 - 2031, USD Million
  • TABLE 85 Rest of LAMEA T-cell Lymphoma Market by Peripheral Type, 2020 - 2023, USD Million
  • TABLE 86 Rest of LAMEA T-cell Lymphoma Market by Peripheral Type, 2024 - 2031, USD Million
  • TABLE 87 Rest of LAMEA T-cell Lymphoma Market by Therapy, 2020 - 2023, USD Million
  • TABLE 88 Rest of LAMEA T-cell Lymphoma Market by Therapy, 2024 - 2031, USD Million
  • TABLE 89 Key Information - Bristol Myers Squibb Company
  • TABLE 90 Key Information - Daiichi Sankyo Company, Limited
  • TABLE 91 Key Information - Eisai Co., Ltd.
  • TABLE 92 Key Information - Acrotech Biopharma Inc.
  • TABLE 93 Key Information - Shenzhen Chipscreen Biosciences Co., Ltd.
  • TABLE 94 Key Information - Citius Pharmaceuticals, Inc.
  • TABLE 95 Key Information - Genor Biopharma Co. Ltd
  • TABLE 96 Key Information - Innate Pharma SA
  • TABLE 97 Key Information - Dizal Pharmaceutical Co. Ltd.
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!